Latest Insider Transactions at An2 Therapeutics, Inc. (ANTX)
This section provides a real-time view of insider transactions for An2 Therapeutics, Inc. (ANTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of AN2 Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of AN2 Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 10
2022
|
Eric Easom Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,413
-47.23%
|
$66,195
$15.32 P/Share
|
|
Nov 09
2022
|
Eric Easom Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
10,111
-67.33%
|
$151,665
$15.61 P/Share
|
|
Nov 08
2022
|
Eric Easom Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,055
-16.99%
|
$105,825
$15.9 P/Share
|
|
Nov 07
2022
|
Eric Easom Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
12,203
-44.37%
|
$195,248
$16.31 P/Share
|
|
Nov 04
2022
|
Eric Easom Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
8,828
-34.04%
|
$132,420
$15.8 P/Share
|
|
Nov 03
2022
|
Eric Easom Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
14,165
-19.13%
|
$212,475
$15.85 P/Share
|
|
Nov 02
2022
|
Eric Easom Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,544
-23.93%
|
$23,160
$15.07 P/Share
|
|
Oct 31
2022
|
Eric Easom Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,688
-29.41%
|
$40,320
$15.39 P/Share
|
|
Oct 28
2022
|
Eric Easom Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,683
-25.54%
|
$25,245
$15.09 P/Share
|
|
Oct 27
2022
|
Eric Easom Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
924
-12.3%
|
$13,860
$15.36 P/Share
|
|
Oct 26
2022
|
Eric Easom Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,678
-25.48%
|
$25,170
$15.1 P/Share
|
|
Oct 25
2022
|
Eric Easom Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,806
-22.5%
|
$72,090
$15.95 P/Share
|
|
Oct 24
2022
|
Eric Easom Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,866
-20.1%
|
$45,856
$16.17 P/Share
|
|
Oct 21
2022
|
Eric Easom Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,951
-46.95%
|
$223,216
$16.49 P/Share
|
|
Oct 20
2022
|
Eric Easom Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,293
-13.97%
|
$116,688
$16.92 P/Share
|
|
Aug 04
2022
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
100
+0.0%
|
$700
$7.99 P/Share
|
|
Aug 03
2022
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,809
+0.05%
|
$12,663
$7.48 P/Share
|
|
Jul 27
2022
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
8,281
+0.22%
|
$57,967
$7.91 P/Share
|
|
Jul 26
2022
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
14,938
+0.4%
|
$104,566
$7.71 P/Share
|
|
Jun 21
2022
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
302
+0.01%
|
$2,114
$7.99 P/Share
|
|
Jun 14
2022
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
61,424
+1.61%
|
$429,968
$7.97 P/Share
|
|
Jun 13
2022
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
20,000
+0.54%
|
$140,000
$7.9 P/Share
|
|
Jun 06
2022
|
Adjuvant Global Health Technology Fund, L.P. |
BUY
Other acquisition or disposition
|
Indirect |
26,511
+6.03%
|
$397,665
$15.0 P/Share
|
|
Jun 06
2022
|
Adjuvant Global Health Technology Fund, L.P. |
SELL
Other acquisition or disposition
|
Direct |
26,511
-1.2%
|
$397,665
$15.0 P/Share
|
|
Jun 06
2022
|
Kabeer Aziz |
BUY
Other acquisition or disposition
|
Indirect |
26,511
+6.03%
|
$397,665
$15.0 P/Share
|
|
Jun 06
2022
|
Kabeer Aziz |
SELL
Other acquisition or disposition
|
Indirect |
26,511
-1.2%
|
$397,665
$15.0 P/Share
|
|
Mar 29
2022
|
Kabeer Aziz |
BUY
Open market or private purchase
|
Indirect |
166,666
+7.01%
|
$2,499,990
$15.0 P/Share
|
|
Mar 29
2022
|
Kabeer Aziz |
BUY
Conversion of derivative security
|
Indirect |
2,430,714
+33.05%
|
-
|
|
Mar 29
2022
|
Eric Easom Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
4,907
+50.0%
|
-
|
|
Mar 29
2022
|
Adjuvant Global Health Technology Fund, L.P. |
BUY
Open market or private purchase
|
Indirect |
166,666
+7.01%
|
$2,499,990
$15.0 P/Share
|
|
Mar 29
2022
|
Adjuvant Global Health Technology Fund, L.P. |
BUY
Conversion of derivative security
|
Indirect |
2,430,714
+33.05%
|
-
|
|
Mar 29
2022
|
Robin Shane Readnour |
BUY
Open market or private purchase
|
Indirect |
153,334
+14.49%
|
$2,300,010
$15.0 P/Share
|
|
Mar 29
2022
|
Robin Shane Readnour |
BUY
Conversion of derivative security
|
Indirect |
751,621
+32.53%
|
-
|
|
Mar 29
2022
|
Joseph S Zakrzewski |
BUY
Conversion of derivative security
|
Direct |
98,199
+50.0%
|
-
|
|
Mar 29
2022
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,666,666
+27.03%
|
$24,999,990
$15.0 P/Share
|
|
Mar 29
2022
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
1,999,997
+50.0%
|
-
|